Intarcia Overview

  • Founded

  • 1995

Founded
  • Status

  • Out of Business

  • Employees

  • 240

Employees
  • Latest Deal Type

  • Liquidation

Intarcia General Information

Description

Developer of drug therapies intended to deliver an improved therapeutic outcome while enhancing patients' quality of life. The company's proprietary subcutaneous delivery system comprises three unique technologies, including a stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, enabling patients to avail necessary treatment required for chronic serious disorders in the field of diabetes, obesity and autoimmune diseases.

Contact Information

Website
www.intarcia.com
Formerly Known As
BioMedicines
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • One Marina Park Drive
  • 13th Floor
  • Boston, MA 02210
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Intarcia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
22. Bankruptcy: Liquidation 01-Nov-2020 00.000 Completed Bankruptcy: Liquidation
21. Later Stage VC 14-Jan-2020 00000 00.000 Completed Profitable
20. Later Stage VC (Series EE) 03-Aug-2017 00000 00.000 00.000 Completed Profitable
19. Later Stage VC (Series DD) 01-May-2017 00.000 Completed Profitable
18. Later Stage VC (Series CC) 27-May-2016 00000 00.000 Completed Profitable
17. Debt - General 06-May-2016 0000 00000 Completed Profitable
16. Later Stage VC (Series DD) 27-Mar-2014 00000 00000 00.000 Completed Clinical Trials - Phase 3
15. Later Stage VC (Series B2) 00000 Completed Clinical Trials - Phase 3
14. Later Stage VC (Series B1) $445M Completed Clinical Trials - Phase 3
13. Later Stage VC (Series AA) 08-Jan-2013 $445M Completed Clinical Trials - Phase 3
To view Intarcia’s complete valuation and funding history, request access »

Intarcia Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series EE 00,000,000 00.000000 00 000 000 00 000 00.000
Series DD 0,000,000 00.000000 00 000.00 000.00 00 000.00 0.000
Series CC 00,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series BB3 000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series BB2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series BB1 3,833,865 $0.001000 8% $6 $6 1x $6 5.6%
Series AA 3,180,135 $0.001000 8% $6 $6 1x $6 4.64%
To view Intarcia’s complete cap table history, request access »

Intarcia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drug therapies intended to deliver an improved therapeutic outcome while enhancing patients' quality of lif
Drug Delivery
Boston, MA
240 As of 2018
00.000
000000000000 00.000

000000

n reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
0000 000000000
Waltham, MA
000 As of 0000
00000
000000 - 000 00000

000000

qua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
0000 000000000
Rockville, MD
0 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Intarcia Competitors (61)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apellis Formerly VC-backed Waltham, MA 000 00000 000000 - 000 00000
000000000 00000000 Venture Capital-Backed Rockville, MD 0 000.00 0000000000 0 000.00
00 00000000 Formerly VC-backed Glasgow, United Kingdom 00 000.00 00000000 000.00
0000 Formerly PE-Backed Vancouver, Canada 00 00000 000000000 00000
0000000 Venture Capital-Backed Niel, Belgium 00 00000 00000000000 00000
You’re viewing 5 of 61 competitors. Get the full list »

Intarcia Patents

  • 666

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 31

    Granted

  • 3

    Pending

  • 000

    Expiring in next 12 mo

Intarcia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230063420-A1 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use Pending 17-Dec-2020 0000000000
AU-2019357621-A1 Human amylin analog polypeptides and methods of use Pending 11-Oct-2018 0000000000
CA-3116023-A1 Human amylin analog polypeptides and methods of use Pending 11-Oct-2018 0000000000
EP-3864031-A1 Human amylin analog polypeptides and methods of use Pending 11-Oct-2018 0000000000
US-20200115430-A1 Human amylin analog polypeptides and methods of use Pending 11-Oct-2018 C07K14/575 0
To view Intarcia’s complete patent history, request access »

Intarcia Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Intarcia Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 24-Sep-2015 0000000000 Drug Discovery 0000 0000
000000000000 01-Apr-2003 00000 0000 000.00 Pharmaceuticals
000000000000 01-Nov-2000 00000 0000 0000 Pharmaceuticals
Cytokinetics 01-Aug-1999 Early Stage VC 0000 Pharmaceuticals
To view Intarcia’s complete investments and acquisitions history, request access »

Ready to get started?

Request a free trial

Intarcia Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000000000 01-Apr-2003 00000 00000 00 000.00 Completed
  • 11 buyers
000000000000 01-Nov-2000 00000 00000 00 0000 Completed
  • 6 buyers
Cytokinetics 01-Aug-1999 Early Stage VC 0000 Completed
  • 4 buyers
To view Intarcia’s complete exits history, request access »